Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | GPR183 | P32249 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ATF4 | P18848 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19709040 | 0.86 | HPGD (0.97) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL655198 | 0.85 | ALDH1A1 (0.69) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL652552 | 0.84 | MEN1 (0.78) | POLBMAPTMEN1KMT2AGPR183 | |
| SCHEMBL19705176 | 0.84 | HPGD (1.00) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL793748 | 0.83 | POLB (0.75) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL6783893 | 0.82 | POLB (0.73) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL15134812 | 0.82 | POLB (0.73) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL170018 | 0.82 | TPSAB1 (0.76) | POLBHPGDMAPTRAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL16825661 | 0.81 | TPSAB1 (0.74) | POLBHPGDMAPTRAB9AMEN1 | |
| SCHEMBL5066354 | 0.79 | LMNA (0.76) | POLBHPGDMAPTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2923734-B1 | PURINE ANALOGUES AND THEIR USE AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-02-04 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | disclosed |
| US-20110123486-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | disclosed |
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2009002553-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1999116-A2 | 3-ARYL-SUBSTITUTED QUINAZOLONES, AND USES THEREOF | Prolexys Pharmaceuticals, Inc. (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007076087-A2 | 3-ARYL-SUBSTITUTED QUINAZOLONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076085-A2 | FUSED PYRIMIDONES AND THIOPYRIMIDONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC . (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | POLB 4582/4885HPGD 2507/4885MAPT 3607/4885 |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | MKI67, MCL1, HCCS | POLB 689/4885HPGD 345/4885MAPT 4490/4885 |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | POLB 4582/4885HPGD 2507/4885MAPT 3607/4885 |
| US-20110123486-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | MCL1, BCL3, DDIT3 | POLB 2914/4885HPGD 1342/4885MAPT 4472/4885 |
| US-20090170834-A1 | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof | TYMP, TYMS, MKI67 | POLB 228/4885HPGD 537/4885MAPT 4007/4885 |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | RNASE1, HAVCR2, RNASEH1 | POLB 1180/4885HPGD 2078/4885MAPT 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.